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Abstract
Background: One of the most important risk factors for stroke is hypertension. A number of studies have
attempted to identify the most effective anti-hypertensive therapeutic group for stroke prevention. Using an
epidemiologic approach we aimed to find correlations based on Hungarian data on stroke-mortality and on
prescription routine of anti-hypertensive therapeutics in three different counties, showing significant difference in
stroke mortality.
Methods: We have used the official yearly reports on stroke-mortality for the period 2003-2008. Based on the
significant differences in the change in mortality due to stroke three counties were selected: Baranya, Bekes and
Hajdu-Bihar. The usage of antihypertensive therapeutic groups was analyzed. The correlation of stroke mortality
difference and different antihypertensive treatment habits was analyzed by using normality test, time series
analyses, correlation coefficient, paired samples test, one sample test and chi-square test.
Results: For the year 2003 stroke-mortality standardized with the county population number was highest in county
Bekes, followed by county Baranya and county Hajdu-Bihar. For each year stroke mortality has shown significant (p <
0.0001) difference between the three counties and the ranking/order of the counties has been preserved over time.
During the period of our study, an increase in the number of days of treatment was observed for most of the anti-
hypertensive drugs listed. We have observed that the increased use of high-ceiling diuretics resulted in a mortality
advantage, and the reduction in use of calcium channel blockers with direct cardiac effect had negative consequences.
Conclusions: The authors acknowledge that by limiting the study to three counties the findings cannot be
generalized to the whole Hungarian population. Two trends can still be identified:
i) increased number of days of treatment (and therefore the probable use) of high-ceiling diuretics is associated
with reduction in mortality due to stroke and its immediate complications; ii) reduction in the use of non-
dihidropiridin CCBs does not seem justified, as their use appears to be advantageous in stroke prevention. Authors
put emphasis on the importance of the adherence of the patients to the preventive therapies. Health care
professionals could provide an important added value to the life long preventive therapies by improving the
compliance of their patients, giving personalized care and advice.
Background
The widespread reduction in cardio-vascular mortality
in the recent past can be ascribed to a number of favor-
able changes. Out of a multitude of contributing factors
we have previously documented the favorable role of the
steady increase in the prescription of cardio-metabolic
therapies [1]. That study described a significant correla-
tion between the increase in prescription of three thera-
peutic groups (anti-diabetic, anti-lipidemic and anti-
hypertensive) and the reduction in mortality due to
stroke and acute myocardial infarction (AMI). Out of
the above mentioned cardio-metabolic therapeutic
groups the most noteworthy increase in prescriptions
was observed for anti-hypertensive drugs. The goal of
our present study is to focus specifically on the correla-
tion between anti-hypertensive prescriptions and
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data collected from three Hungarian counties and com-
pare these data over a period of 6 years.
One of the most important risk factors for stroke is
hypertension. It has been shown that blood pressure
levels higher than 115/75 mmHg display a linear corre-
lation between blood pressure level and mortality and
also morbidity due to stroke [2,3]. In the 40 to 70 years
age group it was shown that a 20 mmHg increase in sys-
tolic blood pressure or a 10 mmHg increase in diastolic
blood pressure double the risk of stroke [4]. Therefore,
reducing blood pressure levels could be one of the most
effective mechanisms for decreasing the incidence of
stroke and mortality due to stroke.
All anti-hypertensive therapeutics reduce the risk of
emergence of stroke and coronary disease and their effi-
cacy correlates with the degree of decrease of systolic
blood pressure levels [5,6]. A number of studies have
attempted to identify the most effective anti-hyperten-
sive therapeutic group for stroke prevention. Meta-ana-
lysis studies have shown that the risk of stroke is
reduced with calcium-channel blockers (CCBs) more,
than the expected levels for a given reduction in the sys-
tolic blood pressure level while beta-blockers reduce
stroke-risk less, than the other anti-hypertensive thera-
peutic drugs [6,7].
Using an epidemiologic approach we aimed to find
correlations based on Hungarian data on stroke-mortal-
ity and on prescription routine of anti-hypertensive
therapeutics.
Methods
We have used the official yearly reports on stroke-mor-
tality for the period 2003-2008 published by the Hun-
garian Central Statistics Office (KSH) [8]. The mortality
statistics provided by KSH are based on death certificate
records and sum up the main diagnoses for cause of
death. Diagnoses used are defined according to the
International Classification of Diseases Tenth Revisions
(ICD-10). The yearly reports contain the mortality data
of Hungarian counties normalized for the population of
each county. Accordingly, our use of the term stroke-
mortality includes fatal stroke and death due to direct
complications of stroke.
Following a preliminary analysis of stroke mortality
changes per 100 000 inhabitants in different counties,
three counties were selected: Baranya, Bekes and Hajdu-
Bihar based on the significant differences in the change
in mortality due to stroke.
Of the 19 counties in Hungary Hajdu-Bihar had the
lowest stroke mortality in the two years: 132.3/100 000
inhabitants in 2003 and 83.2/100 000 inhabitants in
2008. Bekes showed the 2nd highest mortality (200.5/
100 000 inhabitants) in 2008 but compared to the first
highest (Zala county with 212.4/100 000 inhabitants)
showed less improvement (36.5 versus 57.4) during the
6 years of examination. Baranya had the 3rd lowest
stroke mortality rate (124.8/100 000 inhabitants) in 2008
(without considering Hajdu-Bihar which was already
included), but started from a higher level (173,5/100 000
inhabitants) in 2003, so the improvement was higher
(48.7) in this county than in Pest county (32.1) and the
capital Budapest (43.7). So we ended up with three
counties: one (Hajdu-Bihar) with the lowest stroke mor-
tality rates in 2003 and 2008, another (Bekes) with the
lowest improvement among the counties with high mor-
tality rate in 2008, and one (Baranya) with the best
improvement among the ones with lowest mortality rate
in 2008. In order to find out differences in the anti-
hypertensive treatment, and possible association with
the stroke mortality changes, we analyzed these three
counties with different specific patterns of change in
stroke mortality.
The anti-hypertensive therapies we have studied
belong to the following ATC (anatomical, therapeutic
and chemical) groups: centrally acting antiadrenergic
agents (ATC: C02A); peripherally acting antiadrenergic
agents (ATC: C02C); low-ceiling diuretics, thiazides
(ATC: C03A, C03B); high-ceiling diuretics (ATC:
C03C); potassium-sparing agents (ATC: C03D); beta
blocking agents (ATC: C07A); selective calcium channel
blockers with mainly vascular effects (ATC: C08C);
selective calcium channel blockers with direct cardiac
effects (ATC: C08D); plain ACE-inhibitors (ATC:
C09A), plain angiotensin II antagonists (ATC: C09C)
(see Additional file 1).
The usage of these therapeutic groups in each county
was obtained from data provided by the Hungarian
National Health Insurance Fund (OEP) yearly reports
for 2003-2008 [9] compiled yearly and per county from
the dispensing records of all retail pharmacies in Hun-
gary. OEP reports express the use of therapeutic agents
as number of days of treatment (DOT) per ATC group
for each county. DOT values take into account differ-
ences in drug strength and formulation based on the
common denominator of the daily defined dose (DDD)
d e f i n e db yt h eW H O .D u et ot h ec h a r a c t e ro fs o u r c e
data we studied the total usage of therapeutics at county
level, corrected to the county population. Reports do
not contain data on combination therapies and do not
include information on physician characteristics,
patient-level data (e.g. age, sex, co-morbidities, or con-
comitant medications dispensed), or indications for use.
Data were not age and sex standardized.
Both databases [8,9] are freely accessible; no specific
approval was required for use.
The relationship between standardized yearly rates of
mortality per 100 000 inhabitants in each county and
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Page 2 of 6the yearly days of treatment per each therapeutic group
corrected to the county population was examined. This
analysis was designed to assess the association between
the changes in prescriptions and the changes in mortal-
ity rates as a function of time (years). We also deter-
mined the correlation coefficients between the number
of days of treatment and mortality rates. All of the com-
putations were solved using MedCalc and Zaitun Times
Series statistical software. The applied statistical meth-
ods were: Normality test, time series analyses, correla-
tion coefficient, paired samples test, one sample test and
chi-square test.
Results
For the year 2003 stroke-mortality standardized with the
county population number was highest in county Bekes,
f o l l o w e db yc o u n t yB a r a n y aa n dc o u n t yH a j d u - B i h a r
(Figure 1). During the following years mortality
decreased in each county, except for the uniform
increase of small magnitude observed in 2007. For each
year stroke mortality has shown significant (p ≤ 0.0001)
differences between the three counties and the ranking/
order of the counties has been preserved over time. In
all three counties the rate of mortality decrease due to
stroke was different, the most marked change being
observed in county Hajdu-Bihar (Figure 2). During the
period of our study, an increase in the number of days
of treatment was observed for most of the anti-hyper-
tensive drugs listed (Figure 3).
Our analyses show a connection between the changes
in the prescription of different anti-hypertensive drugs
and the decrease over time of mortality due to stroke
for only two of the eleven studied therapeutic groups
(see Additional file 1). The comparison of the number
of days of treatment with high-ceiling diuretics (ATC:
C03C) between county Baranya and county Bekes
showed a bigger increase in diuretics prescription in
county Baranya and a more accentuated decrease in
stroke-mortality was recorded in the same county (see
Additional file 2). In the comparison of counties Bekes
and Hajdu-Bihar in regard to the decrease in the use of
selective calcium channel blockers with direct cardiac
effects we found that in county Hajdu-Bihar, where the
drop in these prescriptions was smaller, stroke-mortality
remained at lower levels (see Additional file 2). Addi-
tional file 3 shows the results of the analysis between
counties for each group of antihypertensive treatment
highlighting the significant difference presented in Addi-
tional file 2. In conclusion, while in the first case the
increased use of high-ceiling diuretics was associated
with a mortality advantage, in the latter case the reduc-
tion in use of C08D-group drugs was linked to negative
consequences.
Discussion
Reduction of high blood pressure is one of the most
important preventive interventions concerning primary
(first) stroke. Blood pressure reduction diminishes cor-
onary risk as well and the scale of blood pressure
decrease correlates with the efficacy of prevention [10].
Former studies have demonstrated that all the thera-
peutic drugs used for the treatment of systolic-and-dia-
stolic hypertension and for the treatment of isolated
systolic hypertension reduce stroke incidence indepen-
dently of the specific medication [5,6]. According to the
BPLTTC meta-analysis, which used data from 29 rando-
mized, controlled studies, the risk of stroke can be
reduced by 30-40% by the use of any anti-hypertensive
treatment [5]. Independently of the actual vascular risk-
status of a patient a reduction by 10 mmHg of the sys-
tolic blood pressure, or by 5 mmHg of the diastolic
blood pressure can reduce the number of coronary
events by approx. 25% and of stroke by approx. 30% [6].
It is widely recognized that differences exist in efficacy
amongst different groups of anti-hypertensive drugs. A
meta-analysis of nine studies showed a 10% -although
not statistically significant- advantage of calcium-chan-
nel blockers (CCBs) over other therapeutic group [11].
The formerly mentioned BPLTTC analysis has docu-
mented that CCBs have a more favorable effect com-
pared to ACE-inhibitors, diuretics or beta-blocking
agents. A later meta-analysis [12] which reviewed 13
studies, comprising in aggregate more than 100,000
patients, found that CCBs reduced the incidence of
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Figure 1 Change of mortality rate (/100,000 inhabitants) in the
three counties during the period 2003-2008.
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Figure 2 Stroke mortality decrease expressed as a percentage
of the 2003-value.
Papp et al. BMC Cardiovascular Disorders 2012, 12:15
http://www.biomedcentral.com/1471-2261/12/15
Page 3 of 6stroke to a greater extent than the other anti-hyperten-
sive drugs. Notably, the CCB-mediated decrease in
stroke-incidence did not directly correlate with their
anti-hypertensive effect. A possible explanation for this
observation could be that CCBs can mitigate the
excessive influx of calcium into neurons, thereby dimin-
ishing neuronal necrosis in ischemic brain regions. The
meta-analysis was able to differentiate between the
CCBs with mainly vascular effects and CCBs which have
a direct cardiac effect. CCBs with mainly vascular effects
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Figure 3 Change in the days of treatment in the three counties (analysed ATC groups on separate diagrams).
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Page 4 of 6were 10% more effective than other anti-hypertensive
drugs, while CCBs with direct cardiac effects were 8%
more effective. The later was not statistically signifi-
cantly different from the efficacy of the other therapeu-
tic groups.
According to the investigators, this result is due to the
inclusion into the meta-analysis of the CONVINCE
study, which was ended prematurely based on trend-like
results which were emerging during the study, and
which casts doubts upon the utilization of these results
[12].
The INVEST [13] and VHAS [14] studies have
reported no differences when comparing the efficacy of
verapamil–a CCB with direct cardiac effects–with beta-
blocking agents [13] or with diuretics [14]. In contrast,
the NORDIL study [15] demonstrated a stronger effect
of the CCB diltiazem compared to both diuretic- and
beta-blocking-therapies with regards to stroke occur-
rence. This difference in efficacy could possibly be
explained by the extent of blood pressure reduction,
which was 3 mmHg greater using diltiazem. Unfortu-
nately, there are no available studies directly comparing
the effects on stroke incidence for drugs belonging to
the two different groups of CCBs.
Non-dihidropiridin CCBs might show an advantage
over CCBs with mainly vascular effects due to their
additional actions such as their ability to reduce heart
rate (with consequently diminished sympathetic nervous
system activation) and their ability to revert left ventri-
cular hypertrophy.
Conclusions
According to the results, the use of CCBs with direct
cardiac effects is associated with a favorable influence
on stroke-mortality in the three Hungarian counties
examined. Our study did not aim to analyze a relation-
ship between drug usage and the incidence of stroke but
drug usage and the mortality connected to stroke. The
stroke-mortality source data for this study reports mor-
tality due to the acute phase of stroke (fatal stroke) and
mortality due to direct complications of stroke as an
aggregate value. Stroke-related mortality in particular is
influenced by the extent of cerebral damage however
cardiac status is also a determining factor. Thus, non-
dihidropiridin CCBs could positively influence both of
these factors, by reducing the degree of cerebral damage
and improving recovery as well as reducing cardiac
effects by mitigating the activation of the sympathetic
nervous system.
The positive correlation between the use of high-ceil-
ing diuretics and decrease in stroke mortality can be
explained mainly by the reduction in blood pressure
levels, however a favorable effect on the associated heart
insufficiency could also be a contributing factor.
Stroke-mortality is influenced by many factors and the
data presented here are intended mainly to raise aware-
ness to some of them. Life-style parameters/measure-
ments and treatments of risk factors other than
hypertension were not included. The overall cardiovas-
cular risk factors of the Hungarian population are likely
to have increased (obesity, diabetes mellitus) while lei-
sure-time physical activity and smoking data did not
change over the studied time frame. The lack of break-
down of these data on a county level made the authors
consider association with anti-hypertensive treatments
only, as the main influencing factor in stroke mortality.
Improvement of the acute care of stroke patients could
also have a positive influence on mortality rates. In the
future a wider analysis of influencing factors could lead
to more precise statements about causes of the differ-
ences experienced amongst counties.
It is reported in meta-analysis studies that CCBs
reduce stroke occurrence to a greater extent than other
anti-hypertensive agents, and this favorable effect likely
extends to mortality due to stroke, both in its acute
phase and post-stroke period. This favorable effect is
probably independent of the CCBs dihidropiridin sub-
classification.
The authors acknowledge that by limiting the study to
three counties the findings cannot be generalized to the
whole Hungarian population. Two trends can still be
identified:
i) increased number of days of treatment (and there-
fore the probable use) of high-ceiling diuretics is asso-
ciated with reduction in mortality due to stroke and its
immediate complications; ii) reduction in the use of
non-dihidropiridin CCBs does not seem justified, as
their use appears to be advantageous in stroke preven-
tion. Although, there are obvious limitations to the pre-
sent study (use of aggregated mortality data; lack of data
regarding combination therapies; lack of county-specific
data on other risk factors such as lifestyle), our findings
are in concordance with the results of the interventional
studies, demonstrating the utility of this kind of assess-
ment. Nevertheless choosing the appropriate medical
treatment has to be accompanied by the personalized
advice and regular control of the patients. The adher-
ence to the life long therapies will give an added value
to the preventive care and increase the quality of life of
the chronically ill patients. The ways the different avail-
able resources are used by the health care system will
result in different outcomes which can be identified
among different geographical areas even in a relatively
small country like Hungary. As the constraint of cost-
effective usage of resources characterizes the actual
health care policies we hope our findings could contri-
bute to the health promotion and better quality of life
of patients with chronic cardiovascular diseases.
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Additional file 1: Table S1. Active ingredients corresponding to the
ATC groups analysed.
Additional file 2: Table S2. Correlation between change in mortality
and drug consumption.
Additional file 3: Table S3. Analysis of correlation between change in
mortality and drug consumption of all ATC groups included.
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